PubRank

E Fressinaud

Author PubWeight™ 52.64‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006 2.56
2 Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992 2.31
3 Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 1996 1.89
4 Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000 1.71
5 Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995 1.58
6 International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost 1993 1.51
7 Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 1999 1.14
8 Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost 2009 1.13
9 A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. Blood 2001 1.13
10 Mapping of X-linked myxomatous valvular dystrophy to chromosome Xq28. Am J Hum Genet 1998 1.07
11 von Willebrand factor ristocetin cofactor activity correlates with platelet function in a high shear stress system. Thromb Haemost 2000 1.07
12 Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost 2000 1.06
13 Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996 1.02
14 New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989 1.02
15 High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998 1.01
16 Willebrand factor and ristocetin. II. Relationship between Willebrand factor, Willebrand antigen and factor VIII activity. Br J Haematol 1974 1.01
17 Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death. Haemophilia 2005 0.99
18 Laboratory diagnosis of von Willebrand disease. Int J Clin Lab Res 1998 0.99
19 Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol 2001 0.96
20 Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol 2001 0.95
21 Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease. Thromb Haemost 1997 0.93
22 French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998 0.90
23 Molecular basis of severe factor XI deficiency in seven families from the west of France. Seven novel mutations, including an ancient Q88X mutation. J Thromb Haemost 2004 0.89
24 Aminophospholipid exposure, microvesiculation and abnormal protein tyrosine phosphorylation in the platelets of a patient with Scott syndrome: a study using physiologic agonists and local anaesthetics. Br J Haematol 1997 0.89
25 Role of platelet membrane glycoproteins and von Willebrand factor in adhesion of platelets to subendothelium and collagen. Ann N Y Acad Sci 1987 0.88
26 Significance of capacitative Ca2+ entry in the regulation of phosphatidylserine expression at the surface of stimulated cells. Biochemistry 1999 0.87
27 Mutations C1157F and C1234W of von Willebrand factor cause intracellular retention with defective multimerization and secretion. J Thromb Haemost 2006 0.87
28 Conformational changes in the D' domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment. Blood 2000 0.86
29 Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype. J Thromb Haemost 2007 0.85
30 [Acquired Willebrand syndrome with lymphoproliferative disorders]. Presse Med 1997 0.84
31 Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis. Haemophilia 2011 0.84
32 Aurin tricarboxylic acid inhibits platelet adhesion to collagen by binding to the 509-695 disulphide loop of von Willebrand factor and competing with glycoprotein Ib. Thromb Haemost 1992 0.83
33 A new automated method for von Willebrand factor antigen measurement using latex particles. Thromb Haemost 1999 0.82
34 Nucleotide substitutions at the -6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: consequences for genetic counseling. Hum Genet 1993 0.82
35 Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. Best Pract Res Clin Haematol 2001 0.81
36 Scott syndrome: an inherited defect of the procoagulant activity of platelets. Platelets 1997 0.81
37 Binding of human von Willebrand factor to collagen and to collagen-stimulated platelets. J Lab Clin Med 1987 0.80
38 von Willebrand factor: structure and function. Mayo Clin Proc 1991 0.80
39 Comparison of anti-human and anti-porcine factor VIII inhibitor levels in 63 patients with severe haemophilia A. A French Multicentric Study. Vox Sang 1993 0.79
40 Identification of a new type 2M von Willebrand disease mutation also at position 1324 of von Willebrand factor. Thromb Haemost 2002 0.79
41 The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor. Blood 2001 0.79
42 Detection of a molecular defect in 40 of 44 patients with haemophilia B by PCR and denaturing gradient gel electrophoresis. Br J Haematol 1993 0.78
43 Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost 1995 0.78
44 Assay of factor VIII antigen (VIII:CAg) in 294 haemophilia A patients by a new commercial ELISA using monoclonal antibodies. Haemophilia 1998 0.78
45 Assessment of the expression of candidate human plasma membrane phospholipid scramblase in Scott syndrome cells. Thromb Haemost 1999 0.78
46 Defects in type IIA von Willebrand disease: a cysteine 509 to arginine substitution in the mature von Willebrand factor disrupts a disulphide loop involved in the interaction with platelet glycoprotein Ib-IX. Br J Haematol 1992 0.77
47 Evaluation of denaturing high-performance liquid chromatography (DHPLC) in the screening of mutations in hemophilia B patients. J Thromb Haemost 2004 0.77
48 First identification and expression of a type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene. J Thromb Haemost 2004 0.76
49 Another link between phospholipid transmembrane migration and ABC transporter gene family, inferred from a rare inherited disorder of phosphatidylserine externalization. Biochem Biophys Res Commun 1997 0.76
50 Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease. Thromb Haemost 2000 0.76
51 Mediation of platelet adhesion to fibrillar collagen in flowing blood by a proteolytic fragment of human von Willebrand factor. Blood 1986 0.76
52 von Willebrand factor collagen binding assay with a commercial kit using type III collagen in von Willebrand disease type 2. J Thromb Haemost 2007 0.76
53 Compound heterozygosity or heterozygosity with two mutations in cis on the same allele? A rebuttal to the letter to the Editors: Koessler et al. Von Willebrand disease caused by compound heterozygosity for p.R854Q and p.R760C: diagnostic and therapeutic implications. Haemophilia 2011; 17: e240-2. Haemophilia 2011 0.75
54 [Hemophilic arthropathies. Apropos of 51 cases]. Ann Pediatr (Paris) 1989 0.75
55 Expression of two type 2N von Willebrand disease mutations identified in exon 18 of von Willebrand factor gene. Br J Haematol 2004 0.75
56 Role of von Willebrand factor in platelet vessel-wall interactions. Ann N Y Acad Sci 1987 0.75
57 [Increase in the frequency of heparin-induced thrombopenia as a result of improved case-finding]. Therapie 1988 0.75
58 [Mesenteric venous thrombosis and antithrombin III deficiency: diagnosis before an acute digestive hemorrhage]. J Mal Vasc 1997 0.75
59 [HIV infection among type A and B hemophiliacs]. Rev Fr Transfus Hemobiol 1993 0.75
60 [A rare hemostatic disorder: pseudo von Willebrand's disease]. Ann Fr Anesth Reanim 1989 0.75
61 [Dental extraction in patients with bleeding disorders. Proposal of a protocol based on the type of anesthesia used]. Rev Stomatol Chir Maxillofac 2003 0.75
62 Somatic mosaicism and compound heterozygosity in female hemophilia B. Blood 2000 0.75
63 [Immunoallergic thrombopenia caused by heparin (apropos of 2 cases, one of which had adrenal insufficiency)]. Cah Anesthesiol 1986 0.75
64 [Initial personal results of a technic of removing leukocytes by filtration on cotton fibers (Imugard Ig 500, Terumo)]. Rev Fr Transfus Immunohematol 1985 0.75
65 Responses of autoimmune factor VIII inhibitors to a combination of cyclophosphamide and prednisone. Blood Coagul Fibrinolysis 1994 0.75
66 [Intracerebral hemorrhage linked to thrombopenia induced by pentosan polysulfate]. Cah Anesthesiol 1988 0.75
67 [Evaluation of a new automated method for von Willebrand factor antigen measurement: the STA-Liatest vWF]. Ann Biol Clin (Paris) 1999 0.75